Research to focus on potential biomarkers of disease progression, immune and treatment response in the setting of Non-Muscle Invasive Bladder Cancer DURHAM, N.C., USA and ROTTERDAM, THE NETHERLANDS, August 5, 2020 — GeneCentric Therapeutics, Inc. and Erasmus University Medical Center (EUMC) today announced that they have entered into a research collaboration to identify RNA-based drug […]

Collaboration will focus on applying advanced RNA-based molecular technologies to predict disease progression and identify potential drug response biomarkers MANHATTAN BEACH, CA and DURHAM, N.C., July 29, 2020 — The Pancreatic Cancer Action Network (PanCAN) and GeneCentric Therapeutics, Inc. today announced that they have entered into a collaborative research partnership for the advancement of RNA-based […]

New molecular analyses to be presented at ASCO Genitourinary Cancers Symposium Durham, NC, February 13, 2020 – GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.  The data are derived from GeneCentric’s expertise in the identification of RNA-based Predictive […]

This three-part webinar series, “Advances in RNA-based Biomarker Development for Precision Oncology”, will highlight trends in RNA-based biomarker development for precision oncology, ranging from the use of gene expression signatures in the development cancer therapies, to the development of RNA-based companion diagnostics, to novel applications for RNA-based biomarkers in cancer treatment. Part 1 is August 24th, with Parts 2 and 3 September 10th and October 8th.

GeneCentric Therapeutics is now located at 100 Capitola Dr, Suite275 Durham, NC 27713

GeneCentric Therapeutics continues to monitor the evolving novel Coronavirus (COVID-19) situation closely. We are following the Centers for Disease Control and Prevention (CDC) recommendations on prevention and spread of the virus along with specific guidance for travelers. Currently, the company doesn’t anticipate any changes with its current client projects and will continuously update clients.

Title: “Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer.” Abstract Number: 458 Date:  February 15, 2019 Presenter: Tracy L. Rose, MD, MPH, Assistant Professor, Division of Hematology/Oncology, UNC Department of Medicine, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC To read the abstract, please visit: https://meetinglibrary.asco.org/record/169672/abstract View the poster here  

Mayhew G, Perou C, Hayes N, Lai-Goldman M, and Faruki H.

Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M.